Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model.

Nivarthi UK, Tu HA, Delacruz MJ, Swanstrom J, Patel B, Durbin AP, Whitehead SS, Pierce KK, Kirkpatrick BD, Baric RS, Nguyen N, Emerling DE, de Silva AM, Diehl SA.

EBioMedicine. 2019 Mar;41:465-478. doi: 10.1016/j.ebiom.2019.02.060. Epub 2019 Mar 8.

2.

Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3.

Campbell RA, Schwertz H, Hottz ED, Rowley JW, Manne BK, Washington AV, Hunter-Mellado R, Tolley ND, Christensen M, Eustes AS, Montenont E, Bhatlekar S, Ventrone CH, Kirkpatrick BD, Pierce KK, Whitehead SS, Diehl SA, Bray PF, Zimmerman GA, Kosaka Y, Bozza PT, Bozza FA, Weyrich AS, Rondina MT.

Blood. 2019 May 9;133(19):2013-2026. doi: 10.1182/blood-2018-09-873984. Epub 2019 Feb 5.

PMID:
30723081
3.

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.

Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, Subbarao K, Diehl SA, Kirkpatrick BD.

PLoS Negl Trop Dis. 2017 May 8;11(5):e0005584. doi: 10.1371/journal.pntd.0005584. eCollection 2017 May.

4.

A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.

Pierce KK, Whitehead SS, Kirkpatrick BD, Grier PL, Jarvis A, Kenney H, Carmolli MP, Reynolds C, Tibery CM, Lovchik J, Janiak A, Luke CJ, Durbin AP, Pletnev AG.

J Infect Dis. 2017 Jan 1;215(1):52-55. doi: 10.1093/infdis/jiw501. Epub 2016 Oct 25.

5.

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.

Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP.

Sci Transl Med. 2016 Mar 16;8(330):330ra36. doi: 10.1126/scitranslmed.aaf1517. Epub 2016 Mar 16.

PMID:
27089205
6.

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.

J Infect Dis. 2016 Sep 15;214(6):832-5. doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16.

7.

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.

J Infect Dis. 2015 Sep 1;212(5):702-10. doi: 10.1093/infdis/jiv082. Epub 2015 Mar 22.

8.

Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model.

Kirkpatrick BD, Lyon CE, Porter CK, Maue AC, Guerry P, Pierce KK, Carmolli MP, Riddle MS, Larsson CJ, Hawk D, Dill EA, Fingar A, Poly F, Fimlaid KA, Hoq F, Tribble DR.

Clin Infect Dis. 2013 Oct;57(8):1106-13. doi: 10.1093/cid/cit454. Epub 2013 Jul 9.

9.

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD.

Vaccine. 2013 Jul 18;31(33):3347-52. doi: 10.1016/j.vaccine.2013.05.075. Epub 2013 Jun 2.

10.

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS.

J Infect Dis. 2013 Mar 15;207(6):957-65. doi: 10.1093/infdis/jis936. Epub 2013 Jan 17.

11.

Capillary hemangioma treatment.

Davies BW, Pierce KK, Holck DE.

Ophthalmology. 2012 Sep;119(9):1938.e1-2. doi: 10.1016/j.ophtha.2012.05.024. No abstract available.

PMID:
22944499
12.

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS.

Vaccine. 2011 Sep 23;29(42):7242-50. doi: 10.1016/j.vaccine.2011.07.023. Epub 2011 Jul 21. Review.

13.

Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infection.

Lindow JC, Poly F, Tribble DR, Guerry P, Carmolli MP, Baqar S, Porter CK, Pierce KK, Darsley MJ, Sadigh KS, Dill EA; Campylobacter Study Team, Kirkpatrick BD.

J Clin Microbiol. 2010 Aug;48(8):3012-5. doi: 10.1128/JCM.00768-10. Epub 2010 Jun 16.

14.

Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well-characterized organism.

Baqar S, Tribble DR, Carmolli M, Sadigh K, Poly F, Porter C, Larsson CJ, Pierce KK, Guerry P; Campylobacter Study Team, Darsley M, Kirkpatrick B.

Clin Vaccine Immunol. 2010 Jan;17(1):80-6. doi: 10.1128/CVI.00252-09. Epub 2009 Nov 18.

15.

Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects.

Tribble DR, Baqar S, Carmolli MP, Porter C, Pierce KK, Sadigh K, Guerry P, Larsson CJ, Rockabrand D, Ventone CH, Poly F, Lyon CE, Dakdouk S, Fingar A, Gilliland T, Daunais P, Jones E, Rymarchyk S, Huston C, Darsley M, Kirkpatrick BD.

Clin Infect Dis. 2009 Nov 15;49(10):1512-9. doi: 10.1086/644622.

PMID:
19842970
16.

Central serous chorioretinopathy associated with the use of ephedra.

Pierce KK, Lane RG.

Retin Cases Brief Rep. 2009 Fall;3(4):376-8. doi: 10.1097/ICB.0b013e31818ad3ce.

PMID:
25389852
17.

Update on human infections caused by intestinal protozoa.

Pierce KK, Kirkpatrick BD.

Curr Opin Gastroenterol. 2009 Jan;25(1):12-7.

PMID:
19119509
18.

Methods for evaluation of peripheral neurovascular dysfunction.

Vinik AI, Erbas T, Park TS, Pierce KK, Stansberry KB.

Diabetes Technol Ther. 2001 Spring;3(1):29-50. Review.

PMID:
11469707
19.

HDO in the Martian atmosphere: implications for the abundance of crustal water.

Yung YL, Wen JS, Pinto JP, Allen M, Pierce KK, Paulson S.

Icarus. 1988;76:146-59.

PMID:
11538666

Supplemental Content

Loading ...
Support Center